

10-21-24 Weekly Clinical Update

FROM CDC:

Current Technical Issues in NHSN

Below is important information regarding current technical issues in the application for the [Respiratory Pathogens and Vaccinations \(RPV\)](#) and [Point of Care \(POC\)](#) modules in the [Long-term Care Facility Component](#) of the National Healthcare Safety Network (NHSN). The NHSN team says they are working hard to resolve these issues as quickly as possible and will inform users when they have been resolved.

Current Issues in the RPV Module

- **Healthcare Personnel (HCP) menu tab: The COVID-19 Vaccination – The HCP tab is not currently visible from the menu when you hover over Respiratory Pathogens and Vaccination on the home page. This form was not removed, and there are no changes in reporting requirements. You can still access this form by clicking RPV Summary and selecting the reporting week from the calendar view.**
- **Analysis and Reporting – HCP: To view HCP COVID-19 Vaccination data, please utilize the report titled “Line Listing - All COVID-19 Vaccination Cumulative Summary Data - HCP” under Respiratory Pathogens and Vaccination > Archived > COVID-19 Vaccination. Currently, the version of this report in the RPV Summary folder is not working appropriately, however the line list mentioned above in the Archived folder will populate the HCP data appropriately.**

Current Issues in the Archived: COVID-19/Respiratory Pathogens Surveillance Pathways Module

There is a technical issue with the COVID-19/Respiratory Pathogens Surveillance Pathways Module preventing users from adding and/or editing data for dates prior to 9/30/24. The issue is occurring for both facility and group users.

Current Issues in the Point of Care Module

There is a technical issue in the Point of Care (POC) test result reporting tool requiring an answer to be selected for gender identity, even though this question is not indicated as a required field for manual test result data entry. *This issue does not affect .csv uploads.*

Additional Questions

If you have any questions regarding the above NHSN modules, please use NHSN-ServiceNow to submit questions to the NHSN Help Desk. The portal can be accessed [here](#) or through your CDC Secure Access Management Services (SAMS) account. After logging into SAMS, the NHSN-ServiceNow is located at the bottom at the bottom of the page.

On another note, on the LTC Infection Prevention Forum, APIC released the Pneumococcal recommendations. Here are there recommendations. Facilities are expected to follow the referenced CDC recommendations:

“1. On June 27, 2024, ACIP recommended the use of the 21-valent pneumococcal conjugate vaccine (PCV21) as an option for adults aged ≥ 19 years who currently have a recommendation to receive a dose of PCV resulting in...

2. The CDC has recommended the use of PCV21 for adults, including nursing home residents, particularly those aged 65 years and older.

- **Routine Vaccination for Adults 65 years and older:** Administer PCV15, PCV20, or PCV21 for all adults 65 years or older...
 - Who have **never received** any pneumococcal conjugate vaccine
 - Whose previous vaccination history is unknown
 - Side note: If PCV15 is used, administer a dose of PPSV23 one year later, if needed. (Considered in adults with an immunocompromising condition, a cochlear implant, a cerebrospinal leak)
 - Another side note: If PCV20 or PCV21 is used, a dose of PPSV23 is NOT indicated.

3. PCV20 & PCV21 are both pneumococcal vaccines with different coverage but are designed to protect against pneumococcal diseases. PCV20 protects against 20 pneumococcal serotypes, while PCV21 adds protection against an additional serotype (21 total). The broader coverage of PCV21 means it may offer additional protection for certain pneumococcal strains. Both vaccines provide strong protection, and the choice between them depends on individual risk factors and healthcare provider recommendations.

- "Shared Clinical Decision-Making" is simply when a healthcare provider collaborates with the patient to make a healthcare decision that is best for the patient's unique situation.
- Shared decision-making allows folks to make an informed choice about whether **additional pneumococcal vaccination** is necessary for their specific situation.
- Based on shared clinical decision-making: Adults aged 65 and older can discuss with their healthcare provider whether to get PCV20 or PCV21 if they have:
 - **Already received** PCV13 (but not PCV15, PCV20, or PCV21), and
 - Have had PPSV23 at or after the age of 65.

I hope this information is helpful and clarifies the guidance.

References:

[Grading of Recommendations, Assessment, Development, and Evaluation \(GRADE\): 21-valent Pneumococcal Conjugate Vaccine \(PCV21\) Use among Adults Aged \$\geq 19\$ Years Who Currently Have a Recommendation to Receive a Pneumococcal Conjugate Vaccine | CDC Pneumococcal Vaccine Recommendations | Pneumococcal | CDC](#)